Emerging therapies such as Totum-63 (Valbiotis), Pep2Dia (Ingredia), and others are expected to impact the Prediabetes market scenario in the upcoming years positively

Prediabetes Market

DelveInsight’s Prediabetes market report offers comprehensive coverage of the current treatment practices, emerging drugs, individual Prediabetes therapy market share, and current and forecasted Prediabetes market size from 2018 to 2030, segmented into 7MM (the United States, EU5 (Germany, Spain, Italy, France, and the UK), and Japan). 

Some of the Key Highlights from the Prediabetes Market Report

• According to the International Diabetes Federation, the global prevalence of prediabetes is expected to rise to 471 million by 2035.

• Key pharmaceutical companies such as Valbiotis, Ingredia, and others are working diligently towards developing novel therapies for Prediabetes.

• Key Prediabetes therapies in the pipeline such as Totum-63, Pep2Dia, and others are expected to enter the market in the upcoming years.

• Valbiotis is developing Totum-63, the major active ingredient in Valedia. It is currently in II/III clinical phase for Prediabetes.

• Pep2Dia is a new health component from Ingredia that helps to manage blood sugar levels after meals. It’s a proprietary milk protein hydrolysate with an active dipeptide AP that’s been formulated specifically for prediabetes to assist control blood sugar and lower levels.

For further information about the disease, request for sample @ Prediabetes Market Research Analysis

The Prediabetes market report also proffers an analysis of the current Prediabetes treatment practice/algorithm, Prediabetes market drivers, Prediabetes market barriers, and unmet medical needs.

Prediabetes Overview

Prediabetes is a dangerous health condition in which blood sugar levels are higher than usual. However, it is not high enough to diagnose type 2 diabetes. Prediabetes, also known as borderline diabetes, is a metabolic disorder closely linked to obesity and is a developing global problem.

Prediabetes Epidemiology Segmentation

The Prediabetes report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

• Prediabetes Prevalent Population

• Prediabetes Age-Specific Prevalent Cases

• Prediabetes Gender-Specific Cases

• Prediabetes Diagnosed and Treatable Population

Prediabetes Treatment Landscape

The rationale for treating prediabetes includes preventing the development of diabetes, avoiding the consequences of diabetes, and avoiding the effects of prediabetes itself.. Metformin, Thiazolidinediones, Glucagon-like peptide-1 analogues, DPP-IV inhibitors, and Alpha-glucosidase inhibitors are used in the current Prediabetes therapy paradigm.

Prediabetes Market

The total Prediabetes market size will include the market size of the potential upcoming therapies such as Totum-63, Pep2Dia, and others and current treatment regimens in the seven major markets.

Get a detailed market analysis @ Prediabetes Market Size

Prediabetes Pipeline Therapies and Key Companies

• Totum-63: Valbiotis

• Pep2Dia: Ingredia

Table of Contents

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Related Reports

Diabetes Market

Get a comprehensive analysis of Diabetes pipeline therapies and key companies such as Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, among others.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/